GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate ; volume:10 ; number:1 ; day:10 ; month:9 ; year:2024 ; pages:1-11 ; date:12.2024
npj Parkinson's Disease ; 10, Heft 1 (10.9.2024), 1-11, 12.2024
- Urheber
-
Argerich, Josep
Garma, Leonardo D.
López-Cano, Marc
Álvarez-Montoya, Paula
Gómez-Acero, Laura
Fernández-Dueñas, Víctor
Muñoz-Manchado, Ana B.
Aso, Ester
Boxer, Adam
Andres-Benito, Pol
Svenningsson, Per
Ciruela, Francisco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-024-00788-x
- URN
-
urn:nbn:de:101:1-2411242111288.301112215620
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Argerich, Josep
- Garma, Leonardo D.
- López-Cano, Marc
- Álvarez-Montoya, Paula
- Gómez-Acero, Laura
- Fernández-Dueñas, Víctor
- Muñoz-Manchado, Ana B.
- Aso, Ester
- Boxer, Adam
- Andres-Benito, Pol
- Svenningsson, Per
- Ciruela, Francisco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Prevention of progression in Parkinson’s disease
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Molekulare Mechanismen der Neurodegeneration bei Morbus Parkinson
Step Length Is a Promising Progression Marker in Parkinson's Disease
Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration
Altered event processing in persons with Parkinson’s disease
Reward processing in Parkinson's disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Prevention of progression in Parkinson’s disease
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Molekulare Mechanismen der Neurodegeneration bei Morbus Parkinson
Step Length Is a Promising Progression Marker in Parkinson's Disease
Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration
Altered event processing in persons with Parkinson’s disease
Reward processing in Parkinson's disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Prevention of progression in Parkinson’s disease
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Molekulare Mechanismen der Neurodegeneration bei Morbus Parkinson
Step Length Is a Promising Progression Marker in Parkinson's Disease
Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages
Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration
Altered event processing in persons with Parkinson’s disease